In February, the US Food and Drug Administration (FDA) issued several notable regulatory decisions over the month spanning obesity treatment devices, endocrine therapies, allergy and immunology, sexual health, and women’s health. The following list details 5 key updates for primary care, including a premarket approval for a swallowable device intended for weight management in adults with obesity, the approval of dupilumab for allergic fungal rhinosinusitis in adults and children aged 6 years and older with a history of sinonasal surgery, labeling revisions removing certain boxed warning risk statements from several menopausal hormone therapy labels, and more.
